News
10-31-2008, 03:22 AM
Researchers of the Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital used the novel inhibitor AZD2281 to target breast cancer, in which the BRCA1-gene plays a role, in a genetically engineered mouse model. Treatment resulted in tumor regression and a strong increase in survival without signs of toxicity. The inhibitor, which recently entered trials in human cancer patients, thus seems to have therapeutic potential for BRCA-defective tumors.
More... (http://www.medicalnewstoday.com/articles/127580.php)
More... (http://www.medicalnewstoday.com/articles/127580.php)